Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1400 of 6351
-
New hope for arthritis sufferers: experimental drug GenSci120 enters Mid-Stage trial
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the efficacy and safety of GenSci1…
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare cholesterol disease: can evinacumab shrink dangerous plaque?
Disease control Recruiting nowThis observational, multicenter, retrospective and prospective study aims to evaluate the impact of intensified lipid-lowering therapy including Evinacumab on coronary atherosclerotic plaque burden in patients with Homozygous Familial Hypercholesterolemia (HoFH). HoFH is a rare …
Sponsor: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Heart-Safe chemo? new study tests vasodilators to prevent chest pain in cancer patients
Disease control Recruiting nowThis phase I/II trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in patients with gastrointestinal cancer receiving fluor…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New depression pill JS1-1-01 enters key trials
Symptom relief Not yet recruitingThe purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
Phase 2/3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
AI brain zaps aim to unlock paralyzed fingers in stroke survivors
Symptom relief Not yet recruitingThe goal of this clinical study is to evaluate whether AI-based customized transcranial direct current stimulation (tDCS) using MR images is more effective than sham stimulation in improving finger motor function in patients with finger paralysis caused by subacute stroke. The ma…
Sponsor: NEUROPHET • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New drug JY016 targets EGFR-Positive cancers in early trial
Disease control Not yet recruitingThis study is a single-arm, open-label, multi-center Phase I/II clinical trial, consisting of Part A: the Phase I dose escalation stage, and Part B: the Phase II expansion stage. The objective of the Phase I dose escalation stage is to evaluate the safety, pharmacokinetic charact…
Phase 1/2 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug SHR-A1904 takes on rare cancer
Disease control Not yet recruitingThis is a prospective, single-center, phase II trial designed to evaluate the efficacy and safety of SHR-A1904 monotherapy in second-line or later treatment of advanced neuroendocrine carcinoma. The primary endpoint is the objective response rate. Secondary endpoints include prog…
Phase 2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Weight-Loss drug semaglutide tested as cannabis craving cure
Disease control Recruiting nowThe HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain …
Phase 2 • Sponsor: Anders Fink-Jensen, MD, DMSci • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to reverse wasting in cancer patients
Symptom relief Not yet recruitingA study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia
Phase 1/2 • Sponsor: Dartsbio Pharmaceuticals Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can starting multiple kidney drugs at once slow Diabetes-Related kidney damage?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to st…
Phase 4 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ES014 targets desmoid tumors in Mid-Stage trial
Disease control Recruiting nowThis is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.
Phase 2 • Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for hard-to-treat blood cancer: BR101 injection enters human testing
Disease control Not yet recruitingThis study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose, safety, pharmacokinetic profile following administration of BR101 injection, and preliminary efficacy in subjects with relapsed or refractor…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Simple scope procedure may prevent radiation damage in recurrent nose cancer
Prevention Not yet recruitingThis study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have received re-irradiation. This is a prospective, single-a…
Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:24 UTC
-
Nanobody-Powered CAR-Ts take on tough lymphoma
Disease control Not yet recruitingThis is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma
Early phase 1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New cell therapy CT1182 takes on tough lymphoma
Disease control Recruiting nowThis study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma (r/r B-NHL).
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could an HIV drug tame brain inflammation in Alzheimer's?
Disease control Recruiting nowThe present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certai…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a vaginal suppository clear High-Risk HPV?
Disease control Recruiting nowThe goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerabili…
Phase 2 • Sponsor: Amplexd Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail aims to beat tough infection in HIV patients
Disease control Not yet recruitingBackground: Disseminated Mycobacterium avium complex (MAC) infection remains a serious opportunistic infection in patients with advanced HIV infection, particularly among those with severe immunosuppression. Despite the widespread use of antiretroviral therapy (ART), disseminate…
Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Ovarian puncture may boost egg count in women with low reserve
Disease control Not yet recruitingA multicenter, prospective, randomized controlled clinical trial. The target population consists of patients undergoing IVF/ICSI artificial reproduction who plan to undergo ovarian stimulation and embryo retrieval (DOR) within 4 months. A stratified block randomization method was…
Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Ancient resin meets modern surgery: could frankincense soothe gum graft wounds?
Symptom relief OngoingThis randomized controlled clinical trial will evaluate the effect of a natural frankincense-based gel on healing of the palatal donor site after soft tissue graft harvesting. A total of 28 adult participants requiring a free gingival graft or connective tissue graft will be rand…
Sponsor: Cairo University • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC